This review discusses the current state of Targeted Alpha Therapy (TAT) in prostate cancer, particularly in mCRPCT (metastatic castration-resistant prostate cancer). This review describes the widely used Radium-223 and the novel trend in the TAT field with a special focus on prostate-specific membrane antigen (PSMA)-based alpha therapy. With this in-depth discussion on the growing field of PSMA-based alpha therapy, we aim also to analyze the most useful diagnostic tools in the patient selection and in the treatment monitoring. We explored the diagnostic tools used in clinical practice and in research settings in order to clarify the imaging procedures that may support the PSMA-based TAT management, including both the patient's selection and the therapy response monitoring, with a special focus on diagnostic PSMA-PET/CT imaging. Further multicenter trials are needed, but a better understanding of the strengths and limitations of molecular imaging in PSMA-based TAT management may help in creating an effective therapeutic algorithm for mCRPC and designing a rational approach to treatment.

The role of PET and SPECT imaging in prostate cancer targeted Alpha therapy: when and how? / Frantellizzi, V; Ricci, M; Cimini, A; Filippi, L; Conte, M; De Feo, Ms; De Vincentis, G. - In: APPLIED SCIENCES. - ISSN 2076-3417. - 13:3(2023). [10.3390/app13031890]

The role of PET and SPECT imaging in prostate cancer targeted Alpha therapy: when and how?

Frantellizzi, V
Primo
;
Conte, M;De Feo, MS
Penultimo
;
De Vincentis, G
Ultimo
2023

Abstract

This review discusses the current state of Targeted Alpha Therapy (TAT) in prostate cancer, particularly in mCRPCT (metastatic castration-resistant prostate cancer). This review describes the widely used Radium-223 and the novel trend in the TAT field with a special focus on prostate-specific membrane antigen (PSMA)-based alpha therapy. With this in-depth discussion on the growing field of PSMA-based alpha therapy, we aim also to analyze the most useful diagnostic tools in the patient selection and in the treatment monitoring. We explored the diagnostic tools used in clinical practice and in research settings in order to clarify the imaging procedures that may support the PSMA-based TAT management, including both the patient's selection and the therapy response monitoring, with a special focus on diagnostic PSMA-PET/CT imaging. Further multicenter trials are needed, but a better understanding of the strengths and limitations of molecular imaging in PSMA-based TAT management may help in creating an effective therapeutic algorithm for mCRPC and designing a rational approach to treatment.
2023
prostate cancer; targeted alpha therapy; 223-radium; Ac-225-PSMA; imaging; SPECT; CT; PET
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
The role of PET and SPECT imaging in prostate cancer targeted Alpha therapy: when and how? / Frantellizzi, V; Ricci, M; Cimini, A; Filippi, L; Conte, M; De Feo, Ms; De Vincentis, G. - In: APPLIED SCIENCES. - ISSN 2076-3417. - 13:3(2023). [10.3390/app13031890]
File allegati a questo prodotto
File Dimensione Formato  
Frantellizzi_The Role of_2023.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.02 MB
Formato Adobe PDF
1.02 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1676185
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact